USA USA: 1-631-626-9181 Europe Europe: 44-208-144-6005  

Search

Tissue samples, tissue arrays, cells, microorganisms, probes and services for your research.

Web Search    Google
Featured Services
Ordering Information

Payment methods we support:
✭ Invoice / Purchase Order
✭ Credit card


Cuprizone Induced Mouse Model

Inquiry

Cuprizone (bis-cyclohexanone oxaldihydrazone) induced mouse model recapitulates several MS pathological features in human, including apoptosis of oligodendrocytes, demyelination, microglia activation and infiltration of macrophages. Typical demyelination can be observed after five weeks of cuprizone exposure in mice. Once cuprizone administration is stopped, spontaneous remyelination will subsequently take place in these model animals. Creative Bioarray focuses on drug research and development services and helps customers explore effective therapeutic approaches targeting demyelination and remyelination in multiple brain regions such as corpus callosum and cerebellum.

Work Flow

Example of the cuprizone induced mouse model study paradigmFigure. 1. Example of the cuprizone induced mouse model study paradigm

Our Capabilities

  • We utilize cuprizone induced mouse model to explore effective therapeutic options for demyelination of the central nervous system.
  • We detect CC demyelination by Luxol Fast Blue (LFB) staining and MRI.
  • We quantitatively assess myelination of the corpus callosum through demyelination score system.
  • We evaluate the number of oligodendrocytes, astrocytes, macrophages and microglia via IHC.

Assays Available

  • Histopathological evaluation
  • LFB staining
  • MRI

With extensive experience in the field of MS, we are confident to help you to overcome any upcoming challenges. Our experts are fully capable of customizing our protocols and assays to meet your specific needs. With our help, we wish to facilitate your research with high efficiency.

Study Examples

Representative pictures show myelination (PLP1 and MBP) in the subcortex and cortex of mouse cerebellum for control, 5 weeks of cuprizone exposure and after 4 weeks of fingolimod/placebo treatment.Figure. 2. Representative pictures show myelination (PLP1 and MBP) in the subcortex and cortex of mouse cerebellum for control, 5 weeks of cuprizone exposure and after 4 weeks of fingolimod/placebo treatment.

Subcortical β-APP (red) and neurofilament (green) staining of control, after 5 weeks of cuprizone exposure and after 4 weeks of recovery.Figure. 3. Subcortical β-APP (red) and neurofilament (green) staining of control, after 5 weeks of cuprizone exposure and after 4 weeks of recovery.

NOGO-A positive mature oligodendrocytes (red) and GFAP-expressing astrocytes (green) in subcortex and cortex in control, 5 weeks of cuprizone exposure and after 4 weeks of recovery.Figure. 4. NOGO-A positive mature oligodendrocytes (red) and GFAP-expressing astrocytes (green) in subcortex and cortex in control, 5 weeks of cuprizone exposure and after 4 weeks of recovery.

Quotation and Ordering

If you have any special needs or questions regarding our services, please feel free to contact us at 631-626-9181 or . We look forward to cooperating with you in the future.

Reference

  1. Maria Nordheim Alme, et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model[J]. Journal of Neuroimmunology, 2015, 285:180-186.


Related Sections

Inflammation & Autoimmune Disease Models:

Multiple Sclerosis (MS) Models:

Customer Support & Price Inquiry
Please input "bioarray" as verification code.
CONTACT US USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-626-9181
Fax: 1-631-614-7828
Email: 

Europe
Tel: 44-208-144-6005
Email: